Prostate cancer patients above the high-risk threshold with a Prolaris score greater than 2.112 saw a statistically significant benefit from multimodality therapy.
Read More
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More
Prostate cancer patients with Decipher high-risk scores received greater benefit from hormonal therapy than those with Decipher low-risk scores.
Read More
Analysis of cell-free DNA in blood samples is revolutionizing cancer treatment and prognosis.
Read More
A Decipher GRID molecular subtyping signature successfully predicted which patients with mHSPC benefited from adding chemotherapy to androgen deprivation hormone therapy.
Read More